Recent research by Escudero et al. comparing tumor markers HE4 and CA125 in healthy individuals (n = 101), patients with nonmalignant lesions (n = 535), and patients with malignant tumors (n = 423) indicated that HE4 has higher specificity in patients with benign gynecological disorders than CA125. This evidence concerns the gene WFDC2 and cancer.